OTCMKTS:ISCOInternational Stem Cell Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding International Stem Cell Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.73 +0.04 (+6.62 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$0.58Now: $0.73▼$0.7350-Day Range$0.60MA: $0.74▼$0.8552-Week Range$0.27Now: $0.73▼$1.20Volume204 shsAverage Volume5,970 shsMarket Capitalization$5.47 millionP/E RatioN/ADividend YieldN/ABeta1.16 ProfileChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort InterestSocial Media International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for International Stem Cell. Previous Next 2.5 Community Rank Outperform VotesInternational Stem Cell has received 111 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInternational Stem Cell has received 112 “underperform” votes. (Add your “underperform” vote.)Community SentimentInternational Stem Cell has received 50.22% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about International Stem Cell and other stocks. Vote “Outperform” if you believe ISCO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ISCO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInternational Stem Cell does not currently pay a dividend.Dividend GrowthInternational Stem Cell does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, International Stem Cell insiders have not sold or bought any company stock.Percentage Held by Insiders81.70% of the stock of International Stem Cell is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.70 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ISCO Previous Symbol CUSIP460378102 CIK1355790 Webwww.internationalstemcell.com Phone760-940-6383Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.54Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.47 million Price / Sales0.58 Cash FlowN/A Price / Cash FlowN/A Book Value($0.38) per share Price / Book-1.91Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,260,000.00 Net Margins-38.82% Return on EquityN/A Return on Assets-49.27%Miscellaneous Employees42 Outstanding Shares7,539,000Market Cap$5.47 million Next Earnings Date8/25/2020 (Estimated) OptionableNot Optionable $0.73 +0.04 (+6.62 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ISCO News and Ratings via Email Sign-up to receive the latest news and ratings for ISCO and its competitors with MarketBeat's FREE daily newsletter. International Stem Cell (OTCMKTS:ISCO) Frequently Asked Questions How has International Stem Cell's stock price been impacted by COVID-19 (Coronavirus)? International Stem Cell's stock was trading at $0.5850 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ISCO stock has increased by 23.9% and is now trading at $0.7250. View which stocks have been most impacted by COVID-19. When is International Stem Cell's next earnings date? International Stem Cell is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for International Stem Cell. How were International Stem Cell's earnings last quarter? International Stem Cell Corp (OTCMKTS:ISCO) announced its quarterly earnings results on Friday, June, 19th. The biotechnology company reported ($0.05) earnings per share for the quarter. The biotechnology company earned $2.36 million during the quarter. View International Stem Cell's earnings history. Has International Stem Cell been receiving favorable news coverage? News headlines about ISCO stock have trended positive on Saturday, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. International Stem Cell earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news about International Stem Cell. Are investors shorting International Stem Cell? International Stem Cell saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 7,000 shares, a decrease of 37.5% from the June 15th total of 11,200 shares. Based on an average daily volume of 7,800 shares, the days-to-cover ratio is presently 0.9 days. View International Stem Cell's Short Interest. Who are some of International Stem Cell's key competitors? Some companies that are related to International Stem Cell include Iterum Therapeutics (ITRM), Uluru (ULUR), MYOS (MYOS), Bio-Path (BPTH), Phio Pharmaceuticals (PHIO), DelMar Pharmaceuticals (DMPI), Sonoma Pharmaceuticals (SNOA), Tetraphase Pharmaceuticals (TTPH), BIOLINERX LTD/S (BLRX), Regulus Therapeutics (RGLS), Akorn (AKRXQ), Salarius Pharmaceuticals (SLRX), Novelion Therapeutics (NVLN), Novelion Therapeutics (NVLNF) and GT Biopharma (GTBP). View all competitors. What other stocks do shareholders of International Stem Cell own? Based on aggregate information from My MarketBeat watchlists, some companies that other International Stem Cell investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Athersys (ATHX), Turkcell Iletisim Hizmetleri A.S. (TKC), Biocept (BIOC), Capricor Therapeutics (CAPR), Canopy Growth (CGC), Neuralstem (CUR), Adesto Technologies (IOTS) and aTyr Pharma (LIFE). Who are International Stem Cell's key executives? International Stem Cell's management team includes the following people: Prof. Andrey Semechkin, Co-Chairman & CEO (Age 59)Dr. Russell Kern, Exec. VP, Chief Scientific Officer & Director (Age 33)Ms. Sophia Garnette J.D., VP of Legal Affairs & Operations and Sec. (Age 35)Mr. Francisco Bustamante, Pres of Lifeline Cell Technology LLC What is International Stem Cell's stock symbol? International Stem Cell trades on the OTCMKTS under the ticker symbol "ISCO." How do I buy shares of International Stem Cell? Shares of ISCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is International Stem Cell's stock price today? One share of ISCO stock can currently be purchased for approximately $0.73. How big of a company is International Stem Cell? International Stem Cell has a market capitalization of $5.47 million and generates $9.47 million in revenue each year. International Stem Cell employs 42 workers across the globe. What is International Stem Cell's official website? The official website for International Stem Cell is www.internationalstemcell.com. How can I contact International Stem Cell? International Stem Cell's mailing address is 5950 PRIESTLY DRIVE, CARLSBAD CA, 92008. The biotechnology company can be reached via phone at 760-940-6383 or via email at [email protected] This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
